Oncolytics Biotech (TSE:ONC) Stock Crosses Above 200 Day Moving Average – Time to Sell?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$1.40 and traded as high as C$1.40. Oncolytics Biotech shares last traded at C$1.40, with a volume of 181,909 shares trading hands.

Analyst Ratings Changes

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The firm has a market capitalization of C$107.60 million, a P/E ratio of -3.68 and a beta of 1.35. The business’s 50 day simple moving average is C$1.38 and its two-hundred day simple moving average is C$1.40.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.